Shiseido Company, Limited
https://corp.shiseido.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shiseido Company, Limited
Five Key Points From Cell & Gene Meeting On The Mesa
The three-day meeting in Carlsbad, CA, included commentary from numerous executives and investors in the cell and gene therapy space. Here are some of the biggest takeaways.
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Finance Watch: Lightstone Ventures Closes $375m Fund To Back Early Stage Biotechs
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
Ulta Teases Developing Program For ‘Clean Beauty’ Shoppers
CEO Mary Dillon noted during Ulta’s fiscal 2019 year-end call the rise of “clean beauty” at a time of growing interest in cosmetic ingredient safety. The retailer aims to provide its customers in 2020 with “a framework to help them evaluate products based on what's most important to them.”
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice